Mineralys Therapeutics (MLYS) Common Equity (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Common Equity of $638.1 million for Q1 2026, down 1.32% sequentially from $646.7 million in Q4 2025, and up 86.83% YoY from $341.6 million in Q1 2025.
Mineralys Therapeutics (MLYS) Common Equity (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Common Equity for 5 years, with the latest figure at $638.1 million in Q1 2026.
- Quarterly Common Equity rose 86.83% year-over-year to $638.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $638.1 million (up 86.83% YoY) and the FY2025 annual result came in at $646.7 million, up 238.13% from the prior year.
- Common Equity retreated to $638.1 million in Q1 2026 per MLYS's latest filing, from $646.7 million in the prior quarter.
- Over five years, Common Equity peaked at $646.7 million in Q4 2025 and troughed at -$52.3 million in Q4 2022.
- A 5-year average of $263.9 million and a median of $285.0 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity surged 1070.88% in 2023, then retreated 20.69% in 2024.
- Over 5 years, Common Equity stood at -$52.3 million in 2022, then surged by 561.37% to $241.2 million in 2023, then slipped by 20.69% to $191.3 million in 2024, then surged by 238.13% to $646.7 million in 2025, then fell by 1.32% to $638.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $638.1 million, $646.7 million, and $576.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 550.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 550.92 Mn |
| Mar 31, 2026 | 638.14 Mn |
| Dec 31, 2025 | 646.69 Mn |
| Sep 30, 2025 | 576.43 Mn |
| Jun 30, 2025 | 313.55 Mn |
| Mar 31, 2025 | 341.56 Mn |
| Dec 31, 2024 | 191.26 Mn |
| Sep 30, 2024 | 236.93 Mn |
| Jun 30, 2024 | 290.10 Mn |
| Mar 31, 2024 | 328.05 Mn |
| Dec 31, 2023 | 241.15 Mn |
| Sep 30, 2023 | 264.01 Mn |
| Jun 30, 2023 | 285.01 Mn |
| Mar 31, 2023 | 295.88 Mn |
| Dec 31, 2022 | -52.27 Mn |
| Sep 30, 2022 | -43.41 Mn |
| Jun 30, 2022 | -36.93 Mn |
| Mar 31, 2022 | -30.48 Mn |